NR4A1 and neoplasm: As expected, 4-year OS rates were significantly lower for patients with hormone receptor negative disease as compared to those with hormone receptor positive (83.3% vs. 91.1%, p = 0.0099), for patients with high-grade tumors (grade III) as compared to those with grade I and II (86.6% vs. 92.4%, p = 0.0085) and for patients who received post-operative radiotherapy as compared to those who did not (88.6% vs. 92.5%, p = 0.0099), probably due to the fact that the latter group had limited lymph-node involvement and smaller tumor size compared to the former.